Inclusion Criteria:

- Stage IIIb and IV NSCLC, excluded squamous cell NSCLC

- Age ≥ 65 years

- ECOG 0-2

Exclusion Criteria:

- Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a
predominant squamous component

- History of haemoptysis

- Evidence of tumour invading major blood vessels on imaging

- Radiotherapy within 28 days prior to enrolment

- Patients who are unable to interrupt aspirin or other nonsteroidal anti-inflammatory
agents, other than an aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day
period for long-acting agents, such as piroxicam)

- Current or recent (within 10 days of first dose of bevacizumab) use of full-dose oral
or parenteral anticoagulants or thrombolytic agent for therapeutic purposes.
Prophylactic use of anticoagulants is allowed

- Clinically significant (i.e. active) cardiovascular disease for example CVA (≤6
months before enrolment), myocardial infarction (≤6 months before enrolment),
unstable angina, CHF NYHA Class ≥II, serious cardiac arrhythmia requiring medication
during the study and might interfere with regularity of the study treatment, or not
controlled by medication

- Non-healing wound, active peptic ulcer or bone fracture

- History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 6 months of enrolment